BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 18761329)

  • 1. Action of resveratrol alone or in combination with roscovitine, a CDK inhibitor, on cell cycle progression in human HL-60 leukemia cells.
    Komina O; Wesierska-Gadek J
    Biochem Pharmacol; 2008 Dec; 76(11):1554-62. PubMed ID: 18761329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resveratrol modulates roscovitine-mediated cell cycle arrest of human MCF-7 breast cancer cells.
    Wesierska-Gadek J; Kramer MP; Maurer M
    Food Chem Toxicol; 2008 Apr; 46(4):1327-33. PubMed ID: 17933449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring of long-term effects of resveratrol on cell cycle progression of human HeLa cells after administration of a single dose.
    Kramer MP; Wesierska-Gadek J
    Ann N Y Acad Sci; 2009 Aug; 1171():257-63. PubMed ID: 19723063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell cycle arrest induced in human breast cancer cells by cyclin-dependent kinase inhibitors: a comparison of the effects exerted by roscovitine and olomoucine.
    Wesierska-Gadek J; Gueorguieva M; Wojciechowski J; Horky M
    Pol J Pharmacol; 2004; 56(5):635-41. PubMed ID: 15591654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of roscovitine, a selective CDK inhibitor, on cancer cells: bi-functionality increases its therapeutic potential.
    Wesierska-Gadek J; Borza A; Komina O; Maurer M
    Acta Biochim Pol; 2009; 56(3):495-501. PubMed ID: 19724778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phenol red reduces ROSC mediated cell cycle arrest and apoptosis in human MCF-7 cells.
    Wesierska-Gadek J; Schreiner T; Gueorguieva M; Ranftler C
    J Cell Biochem; 2006 Aug; 98(6):1367-79. PubMed ID: 16741967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Roscovitine differentially affects asynchronously growing and synchronized human MCF-7 breast cancer cells.
    Maurer M; Komina O; Wesierska-Gadek J
    Ann N Y Acad Sci; 2009 Aug; 1171():250-6. PubMed ID: 19723062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Roscovitine, a selective CDK inhibitor, reduces the basal and estrogen-induced phosphorylation of ER-α in human ER-positive breast cancer cells.
    Węsierska-Gądek J; Gritsch D; Zulehner N; Komina O; Maurer M
    J Cell Biochem; 2011 Mar; 112(3):761-72. PubMed ID: 21328450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual action of cyclin-dependent kinase inhibitors: induction of cell cycle arrest and apoptosis. A comparison of the effects exerted by roscovitine and cisplatin.
    Wesierska-Gadek J; Gueorguieva M; Horky M
    Pol J Pharmacol; 2003; 55(5):895-902. PubMed ID: 14704484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pleiotropic effects of selective CDK inhibitors on human normal and cancer cells.
    Wesierska-Gadek J; Hajek SB; Sarg B; Wandl S; Walzi E; Lindner H
    Biochem Pharmacol; 2008 Dec; 76(11):1503-14. PubMed ID: 18761330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of farnesyl protein transferase sensitizes human MCF-7 breast cancer cells to roscovitine-mediated cell cycle arrest.
    Wesierska-Gadek J; Maurer M; Schmid G
    J Cell Biochem; 2007 Oct; 102(3):736-47. PubMed ID: 17415788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Roscovitine up-regulates p53 protein and induces apoptosis in human HeLaS(3) cervix carcinoma cells.
    Wesierska-Gadek J; Wandl S; Kramer MP; Pickem C; Krystof V; Hajek SB
    J Cell Biochem; 2008 Dec; 105(5):1161-71. PubMed ID: 18846503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Roscovitine-activated HIP2 kinase induces phosphorylation of wt p53 at Ser-46 in human MCF-7 breast cancer cells.
    Wesierska-Gadek J; Schmitz ML; Ranftler C
    J Cell Biochem; 2007 Mar; 100(4):865-74. PubMed ID: 17203463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tamoxifen enhances the anti-proliferative effect of roscovitine, a selective cyclin-dependent kinase inhibitor, on human ER-positive human breast cancer cells.
    Gritsch D; Maurer M; Zulehner N; Wesierska-Gadek J
    J Exp Ther Oncol; 2011; 9(1):37-45. PubMed ID: 21275264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome of treatment of human HeLa cervical cancer cells with roscovitine strongly depends on the dosage and cell cycle status prior to the treatment.
    Wesierska-Gadek J; Borza A; Walzi E; Krystof V; Maurer M; Komina O; Wandl S
    J Cell Biochem; 2009 Apr; 106(5):937-55. PubMed ID: 19180585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reconstitution of human MCF-7 breast cancer cells with caspase-3 does not sensitize them to action of CDK inhibitors.
    Węsierska-Gądek J; Hackl S; Zulehner N; Maurer M; Komina O
    J Cell Biochem; 2011 Jan; 112(1):273-88. PubMed ID: 21080333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of anti-estrogen combined with roscovitine, a selective CDK inhibitor, on human breast cancer cells differing in expression of ER.
    Zulehner N; Maurer M; Wesierska-Gadek J
    J Exp Ther Oncol; 2011; 9(1):17-25. PubMed ID: 21275262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interference with ER-α enhances the therapeutic efficacy of the selective CDK inhibitor roscovitine towards ER-positive breast cancer cells.
    Węsierska-Gądek J; Gritsch D; Zulehner N; Komina O; Maurer M
    J Cell Biochem; 2011 Apr; 112(4):1103-17. PubMed ID: 21308739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process.
    Yu C; Rahmani M; Dai Y; Conrad D; Krystal G; Dent P; Grant S
    Cancer Res; 2003 Apr; 63(8):1822-33. PubMed ID: 12702569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Caspase-3 plays a required role in PC12 cell apoptotic death induced by roscovitine].
    Gao JX; Zhou YQ; Zhang RH; Ma XL; Liu KJ
    Sheng Li Xue Bao; 2005 Dec; 57(6):755-60. PubMed ID: 16344902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.